S271: AN UPDATED FOLLOW-UP OF BRL-101, CRISPR-CAS9-MEDIATED GENE EDITING OF THE BCL11A ENHANCER FOR TRANSFUSION-DEPENDENT BETA-THALASSE
Bin Fu,
Xinhua Zhang,
LI Wang,
Jiaoyang Liao,
Shuanghong Chen,
Biao Zheng,
Wei LI,
Fei Wang,
Dali LI,
Mingyao Liu,
Yuxuan Wu
Affiliations
Bin Fu
1 Xiangya Hospital, Central South University, Hunan, China
Xinhua Zhang
2 923rd Hospital of the People’s Liberation Army, Guangxi, China
LI Wang
2 923rd Hospital of the People’s Liberation Army, Guangxi, China
Jiaoyang Liao
3 Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
Shuanghong Chen
3 Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
Biao Zheng
4 BRL Medicine Inc., Shanghai, China
Wei LI
4 BRL Medicine Inc., Shanghai, China
Fei Wang
4 BRL Medicine Inc., Shanghai, China
Dali LI
3 Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
Mingyao Liu
3 Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
Yuxuan Wu
3 Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
